Maneet Bhatia

Maneet Bhatia

Auto-generated profile, based on publicly available information

Maneet Bhatia

Centre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Translational Research Institute, Woolloongabba, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Redox Biology
Verified
Journal Article
Open access
MBManeet Bhatia
Maneet Bhatia
KMKelly L. McGrath
Kelly L. McGrath
GTGiovanna Di Trapani
Giovanna Di Trapani
PCPornpimol Charoentong
Pornpimol Charoentong
FSFenil Shah
Fenil Shah
KTKathryn F Tonissen
Kathryn F Tonissen
Metastasis is the most life threatening aspect of breast cancer. It is a multi-step process involving invasion and migration of primary tumor cells with a subsequent colonization of these cells at a secondary location. The aim of the present study was to investigate the role of thioredoxin (Trx1) in the invasion and migration of breast cancer cells and to assess the strength of the association between high levels of Trx1 and thioredoxin reductase (TrxR1) expression with breast cancer patient survival. Our results indicate that the expression of both Trx1 and TrxR1 are statistically significantly increased in breast cancer patient cells compared with paired normal breast tissue from the same patient. Over-expression of Trx1 in MDA-MB-231 breast cancer cell lines enhanced cell invasion in in vitro assays while expression of a redox inactive mutant form of Trx1 (designated 1SS) or the antisense mRNA inhibited cell invasion. Addition of exogenous Trx1 also enhanced cell invasion, while addition of a specific monoclonal antibody that inhibits Trx1 redox function decreased cell invasion. Over-expression of intracellular Trx1 did not increase cell migration but expression of intracellular 1SS inhibited migration. Addition of exogenous Trx1 enhanced cell migration while 1SS had no effect. Treatment with auranofin inhibited TrxR activity, cell migration and clonogenic activity of MDA-MB-231 cells, while increasing reactive oxygen species (ROS) levels. Analysis of 25 independent cohorts with 5910 patients showed that Trx1 and TrxR1 were both associated with a poor patient prognosis in terms of overall survival, distant metastasis free survival and disease free survival. Therefore, targeting the Trx system with auranofin or other specific inhibitors may provide improved breast cancer patient outcomes through inhibition of cancer invasion and migration.

29 January 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ESEsha T Shah
Esha T Shah
CMChristopher Molloy
Christopher Molloy
MGMadeline Gough
Madeline Gough
TKThomas Kryza
Thomas Kryza
SSSelwin G. Samuel
Selwin G. Samuel
MAMark Adams
Mark Adams
Background: 5-Fluorouracil (5-FU) remains a core component of systemic therapy for colorectal cancer (CRC). However, response rates remain low, and development of therapy resistance is a primary issue. Combinatorial strategies employing a second agent to augment the therapeutic effect of chemotherapy is predicted to reduce the incidence of treatment resistance and increase the durability of response to therapy.Methods: Here, we employed quantitative proteomics approaches to identify novel druggable proteins and molecular pathways that are deregulated in response to 5-FU, which might serve as targets to improve sensitivity to chemotherapy. Drug combinations were evaluated using 2D and 3D CRC cell line models and an ex vivo culture model of a patient-derived tumour.Results: Quantitative proteomics identified upregulation of the mitosis-associated protein Aurora B (AURKB), within a network of upregulated proteins, in response to a 24 h 5-FU treatment. In CRC cell lines, AURKB inhibition with the dihydrogen phosphate prodrug AZD1152, markedly improved the potency of 5-FU in 2D and 3D in vitro CRC models. Sequential treatment with 5-FU then AZD1152 also enhanced the response of a patient-derived CRC cells to 5-FU in ex vivo cultures.Conclusions: AURKB inhibition may be a rational approach to augment the effectiveness of 5-FU chemotherapy in CRC.

1 October 2016 in European Journal of Cell Biology
Verified
Journal Article
Closed access
MBManeet Bhatia
Maneet Bhatia
CLCarrie J. Lovitt
Carrie J. Lovitt
PRPrahlad Raninga
Prahlad Raninga
VAVicky Avery
Vicky Avery
GTGiovanna Di Trapani
Giovanna Di Trapani
KTKathryn F Tonissen
Kathryn F Tonissen

23 January 2013
Verified
Book Chapter
Open access
PDF file
MBManeet Bhatia
Maneet Bhatia
TCTherese C.
Therese C.
GDGiovanna Di
Giovanna Di
KFKathryn F.
Kathryn F.
The Interaction Between Redox and Hypoxic Signalling Pathways in the Dynamic Oxygen Environment of Cancer Cells | InTechOpen, Published on: 2013-01-23. Authors: Maneet Bhatia, Therese C. Karlenius, Giovanna Di Trapani, et